Karyopharm Aims for Accelerated Approval of Selinexor-Ruxolitinib Combo in Myelofibrosis — Karyopharm Therapeutics Inc.

Event summary

Karyopharm plans to submit a supplemental New Drug Application (sNDA) in August 2026 for selinexor plus ruxolitinib in myelofibrosis under the accelerated approval pathway.
The submission is based on compelling SVR35 data and preliminary overall survival data from the Phase 3 SENTRY trial.
Karyopharm intends to request Priority Review, which could result in a PDUFA target action date approximately six months after FDA receipt of the application.
If approved, this would be the first approved combination therapy for myelofibrosis.

The big picture

Karyopharm's move to seek accelerated approval for this combination therapy marks a significant step in addressing the unmet needs in myelofibrosis treatment. The FDA's engagement and the compelling data from the SENTRY trial highlight the potential for selinexor to redefine frontline treatment paradigms. Success here could position Karyopharm as a key player in the rare blood cancer space, with broader implications for its pipeline of XPO1 inhibitors.

What we're watching

Regulatory Pathway: Whether the FDA will grant accelerated approval based on SVR35 as a surrogate endpoint and the timing of the Priority Review decision.
Clinical Validation: The long-term overall survival data from the SENTRY trial to verify clinical benefit, which is critical for sustained market access.
Market Impact: The potential adoption of selinexor plus ruxolitinib as a new standard of care in myelofibrosis, given its novel mechanism of action.